The Growing Burden of Cancer in Adolescent and Young Adults in Asia: A Call to Action

Malik, Monica; Valiyaveettil, Deepthi; Joseph, Deepa

doi:10.1089/jayao.2023.0008

Cited by 2 publications

(3 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22 Predictors were similar in Pennsylvania. 21 International challenges for AYAs 23 range from high rates of treatment abandonment 24 in Asia to diagnostic and treatment delays across the United Kingdom. 25,26…”

Section: Age and Accessmentioning

confidence: 99%

Access to Care for Adolescents and Young Adults With Cancer in the United States: State of the Literature

Kirchhoff,

Waters,

Chevrier

et al. 2024

JCO

View full text Add to dashboard Cite

Access to care remains a persistent challenge for adolescents and young adults (AYAs) with cancer. We review key findings in the science to date. (1) Location of care matters. There is survival benefit for AYAs treated either at a pediatric center or site with special status (eg, Children's Oncology Group, National Cancer Institute [NCI]–designated Comprehensive Cancer Center). (2) Socioeconomic status and insurance require further investigation. Medicaid expansion has had a moderate effect on AYA outcomes. The dependent care expansion benefit has come largely from improvements in coverage for younger populations whose parents have insurance, while some subgroups likely still face insurance gaps. (3) Clinical trial enrollment remains poor, but access may be improving. Numerous barriers and facilitators of clinical trial enrollment include those that are system level and patient level. NCI has established several initiatives over the past decade to improve enrollment, and newer collaboratives have recently brought together multidisciplinary US teams to increase clinical trial enrollment. (4) Effective AYA programs require provider and system flexibility and program reflection. With flexibility comes a need for metrics to assess program effectiveness in the context of the program model. Centers treating AYAs with cancer could submit a subset of metrics (appropriate to their program and/or services) to maintain their status; persistence would require an entity with staying power committed to overseeing the metrics and the system. Substantial clinical and biological advances are anticipated over the next 20 years that will benefit all patients with cancer. In parallel, it is crucial to prioritize research regarding access to health care and cancer care delivery; only with equitable access to care for AYAs can they, too, benefit from these advances.

show abstract

Section: Age and Accessmentioning

confidence: 99%

Access to Care for Adolescents and Young Adults With Cancer in the United States: State of the Literature

Kirchhoff,

Waters,

Chevrier

et al. 2024

JCO

View full text Add to dashboard Cite

show abstract

“…The treatment of R/R AML in the AYA population remains a challenge for clinicians, despite the progress in the therapeutic evaluation of neoplastic hematologic diseases during recent decades [51,61]. The distinct characteristics of AYA patients combined with the molecular heterogeneity of AML create a difficult hematologic entity to approach [7,8,51,61,96]. Currently, fewer than half of AYA patients survive R/R AML [16,17,95,98].…”

Section: Discussionmentioning

confidence: 99%

“…This evidence could partially be explained by their distinctiveness in biological features, despite the clinical and histopathological similarity of the cancer subtypes, compared to their pediatric and adult counterparts. This, however, favors the use of targeted therapeutic strategies, especially in types of neoplasms that currently remain intractable [7,8].…”

Section: Introductionmentioning

confidence: 99%

Venetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients

Chatzikalil,

Roka,

Diamantopoulos

et al. 2024

JCM

View full text Add to dashboard Cite

Over the past two decades, the prognosis in adolescents and young adults (AYAs) diagnosed with acute myeloid leukemia (AML) has significantly improved. The standard intensive cytotoxic treatment approach for AYAs with AML, consisting of induction chemotherapy with anthracycline/cytarabine combination followed by consolidation chemotherapy or stem cell transplantation, has lately been shifting toward novel targeted therapies, mostly in the fields of clinical trials. One of the most recent advances in treating AML is the combination of the B-cell lymphoma 2 (Bcl-2) inhibitor venetoclax with hypomethylating agents, which has been studied in elderly populations and was approved by the Food and Drug Administration (FDA) for patients over 75 years of age or patients excluded from intensive chemotherapy induction schemas due to comorbidities. Regarding the AYA population, venetoclax combination therapy could be a therapeutic option for patients with refractory/relapsed (R/R) AML, although data from real-world studies are currently limited. Venetoclax is frequently used by AYAs diagnosed with advanced hematologic malignancies, mainly acute lymphoblastic leukemia and myelodysplastic syndromes, as a salvage therapeutic option with considerable efficacy and safety. Herein, we aim to summarize the evidence obtained from clinical trials and observational studies on venetoclax use in AYAs with AML. Based on the available evidence, venetoclax is a safe and effective therapeutic option for R/R AML AYA patients. However, further research in larger cohorts is needed to confirm these data, establishing the benefits of a venetoclax-based regimen for this special population.

show abstract

The Growing Burden of Cancer in Adolescent and Young Adults in Asia: A Call to Action

Cited by 2 publications

References 63 publications

Access to Care for Adolescents and Young Adults With Cancer in the United States: State of the Literature

Access to Care for Adolescents and Young Adults With Cancer in the United States: State of the Literature

Venetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients

Contact Info

Product

Resources

About